Overview

A Placebo-Controlled Trial of D-Cycloserine and Exposure Therapy for Combat-PTSD

Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The primary aim of this project is to examine whether administration of D-Cycloserine (DCS), a partial N-methyl-D-aspartate (NMDA) receptor agonist that has been shown to facilitate fear extinction, enhances the therapeutic benefit of exposure-based cognitive behavioral therapy (CBT) in OEF/OIF veterans with PTSD.
Phase:
N/A
Details
Lead Sponsor:
US Department of Veterans Affairs
VA Office of Research and Development
Treatments:
Cycloserine